Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
7.83
-0.29 (-3.57%)
At close: Sep 12, 2025, 4:00 PM EDT
7.98
+0.15 (1.92%)
After-hours: Sep 12, 2025, 5:05 PM EDT

Gyre Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22
7111,0381,967-
Market Cap Growth
-34.68%-47.22%--
Enterprise Value
6581,0501,946-
Last Close Price
7.8312.1025.69-
PE Ratio
170.7585.93--
PS Ratio
6.639.8217.34-
PB Ratio
7.7310.5525.07-
P/TBV Ratio
8.1716.85--
P/FCF Ratio
--113.23-
P/OCF Ratio
767.18-75.99-
EV/Sales Ratio
6.449.9317.15-
EV/EBITDA Ratio
57.4258.9695.72-
EV/EBIT Ratio
70.4664.73101.27-
EV/FCF Ratio
--111.99-
Debt / Equity Ratio
0.010.020.010.01
Debt / EBITDA Ratio
0.110.090.020.06
Debt / FCF Ratio
--0.020.11
Asset Turnover
0.750.871.13-
Inventory Turnover
0.580.730.89-
Quick Ratio
4.682.642.493.33
Current Ratio
5.403.322.854.06
Return on Equity (ROE)
7.84%20.24%-113.45%-
Return on Assets (ROA)
4.27%8.38%11.93%-
Return on Capital (ROIC)
5.16%11.34%15.83%-
Return on Capital Employed (ROCE)
6.90%15.30%19.90%12.70%
Earnings Yield
0.59%1.16%-4.72%-
FCF Yield
-0.01%-0.57%0.88%-
Buyback Yield / Dilution
-33.83%-55.39%13.02%-
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q